Late Cardiac Pathology in Severe Covid-19. A Postmortem Series of 30 Patients

Abstract

The role of SARS-CoV-2 as a direct cause in the cardiac lesions in patients with severe COVID-19 remains to be established. Our objective is to report the pathological findings in cardiac samples of 30 patients who died after a prolonged hospital stay due to Sars-Cov-2 infection. We performed macroscopic, histological and immunohistochemical analysis of the hearts of 30 patients; and detected Sars-Cov-2 RNA by RT-PCR in the cardiac tissue samples. The median age of our cohort was 69.5 years and 76.6% were male. The median time between symptoms onset and death was 36.5 days. The main comorbidities were arterial hypertension (13 patients, 43.3%), dyslipidemia (11 patients, 36.7%), cardiovascular conditions (8 patients, 26.7%), and obesity (8 patients, 26.7%). Cardiovascular conditions included ischemic cardiopathy in 4 patients (13.3%), hypertrophic cardiomyopathy in 2 patients (6.7%) and valve replacement and chronic heart failure in one patient each (3.3%). At autopsy, the most frequent histopathological findings were coronary artery atherosclerosis (8 patients, 26.7%), left ventricular hypertrophy (4 patients, 13.3%), chronic epicardial inflammation (3 patients, 10%) and adipose metaplasia (2 patients, 6.7%). Two patients showed focal myocarditis, one due to invasive aspergillosis. One additional patient showed senile amyloidosis. Sars-Cov-2 RNA was detected in the heart of only one out of 30 patients, who had the shortest disease evolution of the series (9 days). However, no relevant cardiac histological alterations were identified. In present series, cardiac pathology was only modest in most patients with severe COVID-19. At present, the contribution of a direct effect of SARS-CoV-2 on cardiac lesions remains to be established.

RNA SARS-CoV-2 Persistence in the Lung of Severe COVID-19 Patients: A Case Series of Autopsies

“…These facts support the role of persistent lung viral shedding in lung pathology. Moreover, it might suggest a rapid and short extrapulmonary spread of SARS-CoV-2 in the acute phase of the disease, which is generally cleared without triggering any explosive local inflammatory response in other organs (Ferrer-Gómez et al, 2021;Skok et al, 2021).…”

Risk of Cardiovascular Events After COVID-19

“…24 Frequently observed nonspecific cardiac pathology in COVID-19 highlights the importance of appropriate control in study design assessing CV risks of SARS-CoV-2 infection. 25,26 Of note, any pandemic or epidemic, regardless of the type of a pathogen, might be associated with increased CV mortality. 27 The double cohort design used in this study allowed us to demonstrate the causal nature of SARS-CoV-2 infection with CV events.…”

The emerging role of heart‐on‐a‐chip systems in delineating mechanisms of SARS‐CoV‐2‐induced cardiac dysfunction

“…Infected cardiomyocytes also exhibited decreased expression of sarcomeric ( MYL2 and MYL6 ) and troponin ( TNNT2 and TNNC1 ) genes, which correlated with the dissolution of contractile machinery 45 . These findings align with the significant myofibril abnormalities and clear evidence of damage to the sarcomeric banding in COVID‐19 autopsy samples 45,55,56 …”